

- **Name:** Sook Ryun Park
 - **Current Position & Affiliation:** Professor
Asan Medical Center, University of Ulsan College of Medicine
 - **Country:** Republic of Korea
-

- **Educational Background:**

- Ph.D., Internal Medicine, Seoul National University, Seoul, Korea, 2009
- M.M., Internal Medicine, Seoul National University, Seoul, Korea, 2002
- M.D., Internal Medicine, Seoul National University, Seoul, Korea, 1998

- **Professional Experience:**

- **Secretary General, Korean Society of Medical Oncology (2020-2022)**
- **Professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (2021-current)**
- **Associate Editor, JCO Clinical Cancer Informatics (2021-current)**
- **Associate Editor, Current Problems in Cancer (2020-current)**
- Associate Professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (2015-2021)
- Clinical Assistant Professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (2013-2015)
- Senior Scientist, Division of Translational & Clinical Research I, Research Institute & Hospital, National Cancer Center (2009-2013)
- Associate Scientist, Division of Translational & Clinical Research I, Research Institute & Hospital, National Cancer Center (2007-2009)
- Staff Physician, Center for Gastric Cancer, Research Institute & Hospital, National Cancer Center (2005-2013)
- Visiting Fellow, National Cancer Institute/National Institutes of Health, Bethesda, MD, USA (2010-2012)
- Fellowship in Medical Oncology, Center for Gastric Cancer, Research Institute & Hospital, National Cancer Center (2004-2005)
- Fellowship in Hematology/Oncology, Seoul National University Hospital, Seoul, Korea (2003-2004)

- **Professional Organizations:**

- 2020-2021 International Conference of Korean Society of Medical Oncology, Secretary General
- 2021-2024 Korean National Cancer Control, Sub-Committee Member
- 2018-2020 Korean Society of Medical Oncology, Scientific Committee Member
- 2017-2018 Korean Cancer Association, International Committee Member
- 2017-2018 Korean Society of Medical Oncology, Planning Committee Member
- 2016-2018 Korean Cancer Association, Planning Committee Member

- 2014-2016 Korean Society of Medical Oncology, Publication Committee Member
- 2014-2016 Korean Association of Clinical Oncology, Judging Committee Member
- 2012-2016 Korean Cancer Study Group, External Cooperation Committee Member

• **Main Scientific Publications:**

1. Kim JH, Yoo C, Seo S, Jeong JH, Ryoo BY, Kim KP, Lee JB, Lee KW, Kim JW, Kang M, Ryu H, Cheon J, **Park SR***. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. *Cancers (Basel)* 2022; 22;14(3):559.
2. Kim JH, Seo S, Kim JH, Koh SJ, Ahn Y, Jung KH, Ahn JH, Kim SB, Kim TW, Hong YS, Kim SY, Kim JE, Kim SW, Lee DH, Lee JC, Choi CM, Yoon S, Jeong JH, Kim HJ, Suh KJ, Kim SH, Kim YJ, Min YJ, Baek JH, **Park SR***. The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study. *Cancer Med.* 2022;11(3):705-714.
3. Kim JH, Ahn B, Hong SM, Jung HY, Kim DH, Choi KD, Ahn JY, Lee JH, Na HK, Kim JH, Kim YH, Kim HR, Lee HJ, Kim SB, **Park SR***. Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors. *Cancer Res Treat.* 2022;54(2):505-516.
4. Jeong H, Im HS, Bang Y, Kim YH, Kim HR, Lee HJ, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Lee JH, Ahn JY, Na HK, Ryu JS, Kang J, Kim SB, Kim JH, **Park SR***. Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. *Cancer Med.* 2021;10(5):1745-1758.
5. Jeong H, Im HS, Bang Y, Kim YH, Kim HR, Lee HJ, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Lee JH, Ahn JY, Na HK, Ryu JS, Kang J, Kim SB, Kim JH, **Park SR***. Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. *Cancer Med.* 2021;10(5):1745-1758.
6. Kim EJ, Im HS, Lee J, Cho EH, Kim YH, Kim HR, Kim JH, **Park SR***. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy. *Curr Probl Cancer* 2021;45(3):100685.
7. **Park SR**, Yoon DH, Kim JH, Kim YH, Kim HR, Lee HJ, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Lee JH, Ahn JY, Ryu JS, Cho KJ, Kim SB. A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). *Anticancer Res* 2019;39(9):5123-5133.
8. Oh CR, Kong SY, Im HS, Kim HJ, Kim MK, Yoon KA, Cho EH, Jang JH, Lee J, Kang J, **Park SR***, Ryoo BY*. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. *BMC Cancer* 2019;19(1):292.

9. Park KS, Hong YS, Choi J, Yoon S, Kang J, Kim D, Lee KP, Im HS, Lee CH, Seo S, Kim SW, Lee DH, **Park SR***. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. *BMB Rep* 2018;51(12):660-665.
10. Kim MJ, Kong SY, Nam BH, Kim S, Park YI, **Park SR***. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results. *Pharmacogenet Genomics*. 2018;28(1):23-30.
11. Kim SY, Yoon MJ, Park YI, Kim MJ, Nam BH, **Park SR***. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment. *Gastric Cancer*. 2018;21(3):453-463.
12. **Park SR***, Kim MJ, Nam BH, Kim CG, Lee JY, Cho SJ, Kong SY, Park YI. A randomized phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilization in first-line chemotherapy in patients with metastatic gastric cancer. *Eur J Cancer* 2017;83:32-42.
13. Jeong JH, **Park SR**, Ahn Y, Ryu MH, Ryoo BY, Kong SY, Yook JH, Yoo MW, Kim BS, Kim BS, Kang YK: Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer. *Gastric Cancer*. 2017;20(1):146-155.
14. Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, Cho SJ, Kook MC, Park YI, Kim SK, **Park SR***. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. *Gastric Cancer*. 2016;19(2):586-96.
15. **Park SR**, Park YS, Ryu MH, Ryoo BY, Woo CG, Jung HY, Lee JH, Lee GH, Kang YK. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). *Eur J Cancer*. 2016; 53:42-50.
16. **Park SR**, Davis-Millin M, Doroshow JH, Kummar S. Safety and feasibility of combinations of targeted agents in solid tumors. *Nat Rev Clin Oncol*. 2013;10(3):154-68.
17. Noh SH, **Park SR**, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
18. *Lancet Oncol*. 2014;15(12):1389-96.
19. **Park SR***, Kong S-Y, Nam B-H, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW Kim, Ryu KW, Lee JH, Rhee J, Park Y-I, Kim NK. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. *Br J Cancer* 2011; 104(7):1126-34.

20. **Park SR***, Kong SY, Rhee J, Park YI, Ryu KW, Lee JH, Kim YW, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim NK. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. *Ann Oncol.* 2011;22(4):890-6.
21. Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, Totsuka H, Chiku S, Kuchiba A, Lee YS, Yoon KA, Kook MC, **Park SR**, Kim YW, Tanaka H, Tajima K, Hirose H, Tanioka F, Matsuno Y, Sugimura H, Kato S, Nakamura T, Nishina T, Yasui W, Aoyagi K, Sasaki H, Yanagihara K, Katai H, Shimoda T, Yoshida T, Nakamura Y, Hirohashi S, Sakamoto H. A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. *Gastroenterology.* 2011;140(3):892-902.
22. Kong SY, Lim HS, Nam BH, Kook MC, Kim YW, Ryu KW, Lee JH, Choi IJ, Lee JS, Park YI, Kim NK, **Park SR***. Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. *Pharmacogenomics* 2009;10:1147-1155.
23. Study Group of Millennium Genome Project for Cancer, Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, Saito D, Sugimura H, Tanioka F, Kato S, Matsukura N, Matsuda N, Nakamura T, Hyodo I, Nishina T, Yasui W, Hirose H, Hayashi M, Toshiro E, Ohnami S, Sekine A, Sato Y, Totsuka H, Ando M, Takemura R, Takahashi Y, Ohdaira M, Aoki K, Honmyo I, Chiku S, Aoyagi K, Sasaki H, Ohnami S, Yanagihara K, Yoon KA, Kook MC, Lee YS, **Park SR**, Kim CG, Choi IJ, Yoshida T, Nakamura Y, Hirohashi S. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. *Nat Genet* 2008;40(6):730-40.